PRA Health Sciences is moving into a bigger space in Singapore, consolidating its operations there and looking to boost its share of the growing market for clinical research in Asia.
Scientists believe it might soon be possible to print functioning organs for transplant into humans, according to a recent report in the Southeast Asia Globe. Officials at Singapore's Centre for 3D Printing say they've caught up with Europe and the United States in bioprinting and 3D printing, also known as additive manufacturing, the report said.
Singapore-based TauRx Pharmaceuticals has pulled in $135 million in a fundraising program launched in March, setting the stage for ongoing Phase III trials for a unique Alzheimer's candidate focused on inhibiting the aggregation of tau tangles in the brain.
Novartis will make its heart failure drug Entresto at a Singapore site starting this year, CEO Joe Jimenez told the Straits Times newspaper, adding that plans are also underway to expand contact lens manufacturing in the city-state.
Singapore-listed iX Biopharma reported successful Phase IIa and IIb clinical trials for pain relief lead candidate Wafermine, setting the stage for moving to Phase III, according to the Business Times.
Singapore-based cancer and autoimmune biotech ASLAN Pharmaceutical said it has won clinical trial approval nods in Singapore and Taiwan for Phase II work on ASLAN001 (varlitinib) in second-line cholangiocarcinoma, or aggressive bile duct cancer, marking stepped-up activity for a candidate that recently obtained U.S. FDA orphan designation.
Singapore has gathered pace as a place for companies in Asia to source services related to biologic clinical and manufacturing with recent additions in the city-state highlighting niches in a growing market.
Singapore-listed Asian American Medical Group said it paid S$19.6 million ($13.9 million) to buy 60% of Rich Tree Land to develop an oncology diagnostics and treatment center in Zhuhai, southern China.
Singapore-based ASLAN Pharmaceuticals has received a U.S. FDA orphan designation for candidate ASLAN001 (varlitinib), a pan-HER inhibitor, as a treatment for cholangiocarcinoma, a rare and very aggressive form of bile duct cancer which has no cure, the company said in a press release.
Singapore-based ASLAN Pharmaceuticals has signed an understanding with the National Cancer Centre of Singapore (NCCS) to study novel combination therapies to treat gastric cancer, hepatocellular carcinoma and cholangiocarcinoma, in its second move in this month to explore wider avenues for its existing clinical trial candidates.